|
 |
|
|||||||
|
|||||||||
© 2007 The American Thoracic Society
doi: 10.1513/pats.200703-040BR
Advancing Outcome Measures for the New Era of Drug Development in Cystic Fibrosis
1 Department of Pediatrics, University of Washington; 2 Cystic Fibrosis Therapeutics Development Network Coordinating Center, Children's Hospital and Regional Medical Center; and 3 Department of Biostatistics, University of Washington, Seattle, Washington
Correspondence and requests for reprints should be addressed to Nicole Mayer-Hamblett, Ph.D., Department of Pediatrics, University of Washington, 4800 Sand Point Way N.E., Box 5371, Seattle, WA 98105-0371. E-mail: nicole.hamblett{at}seattlechildrens.org
ABSTRACT
The growing pipeline of candidate drugs for cystic fibrosis (CF) is challenging clinical trial research. There has been a shift from evaluating drugs aimed at treating the secondary manifestations of CF to evaluating drugs targeted toward the primary prevention of chronic lung disease. As CF is an orphan disease, there is a fundamental need to assess new therapies efficiently and accurately by mechanisms that best use the number of available patients. This need can be addressed with the continued advancement and refinement of CF outcome measures. We begin by presenting an overview of the outcome measures currently used in CF clinical studies, defined and categorized in terms of one of the three main classes of endpoints: clinical efficacy measures, surrogate endpoints, and biomarkers. To move forward efficiently, clinical research in CF is dependent on the development of new outcomes able to capture biologic and clinical response to novel therapeutic approaches. We conclude with a discussion of the criteria by which all new outcome measures should be evaluated. A systematic, rigorous approach to outcome measure development is needed to provide the tools necessary for evaluating new therapies and moving drugs out of the pipeline and into the CF clinic.
Key Words: cystic fibrosis • clinical trials • outcome measures • surrogate endpoints • biomarkers
Related articles in Proceedings of the American Thoracic Society:
- Patient-reported Outcomes in Cystic Fibrosis
- Christopher H. Goss and Alexandra L. Quittner
Proceedings of the American Thoracic Society 2007 4: 378-386.[Abstract] [Full Text] - Detection of Cystic Fibrosis Transmembrane Conductance Regulator Activity in Early-Phase Clinical Trials
- Steven M. Rowe, Frank Accurso, and John P. Clancy
Proceedings of the American Thoracic Society 2007 4: 387-398.[Abstract] [Full Text] - Mucociliary Clearance as an Outcome Measure for Cystic Fibrosis Clinical Research
- Scott H. Donaldson, Timothy E. Corcoran, Beth L. Laube, and William D. Bennett
Proceedings of the American Thoracic Society 2007 4: 399-405.[Abstract] [Full Text] - Sputum Biomarkers of Inflammation in Cystic Fibrosis Lung Disease
- Scott D. Sagel, James F. Chmiel, and Michael W. Konstan
Proceedings of the American Thoracic Society 2007 4: 406-417.[Abstract] [Full Text] - Endpoints for Clinical Trials in Young Children with Cystic Fibrosis
- Stephanie D. Davis, Alan S. Brody, Mary J. Emond, Lyndia C. Brumback, and Margaret Rosenfeld
Proceedings of the American Thoracic Society 2007 4: 418-430.[Abstract] [Full Text]
This article has been cited by other articles:
|
|
 |
|
  B. W. Ramsey Outcome Measures for Development of New Therapies in Cystic Fibrosis: Are We Making Progress and What Are the Next Steps? Proceedings of the ATS, August 1, 2007; 4(4): 367 - 369. [Full Text] [PDF]
|
|
|
|
|
|
S. D. Sagel, J. F. Chmiel, and M. W. Konstan Sputum Biomarkers of Inflammation in Cystic Fibrosis Lung Disease Proceedings of the ATS, August 1, 2007; 4(4): 406 - 417. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |